These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15034805)

  • 1. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules.
    Bikfalvi A; Gimenez-Gallego G
    Semin Thromb Hemost; 2004 Feb; 30(1):137-44. PubMed ID: 15034805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet factor 4: an inhibitor of angiogenesis.
    Bikfalvi A
    Semin Thromb Hemost; 2004 Jun; 30(3):379-85. PubMed ID: 15282661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system.
    Bikfalvi A
    Biochem Pharmacol; 2004 Sep; 68(6):1017-21. PubMed ID: 15313395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.
    Hagedorn M; Zilberberg L; Lozano RM; Cuevas P; Canron X; Redondo-Horcajo M; Gimenez-Gallego G; Bikfalvi A
    FASEB J; 2001 Mar; 15(3):550-2. PubMed ID: 11259363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
    Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
    Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2011 Feb; 22(1):1-18. PubMed ID: 21111666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma.
    Bello L; Lucini V; Costa F; Pluderi M; Giussani C; Acerbi F; Carrabba G; Pannacci M; Caronzolo D; Grosso S; Shinkaruk S; Colleoni F; Canron X; Tomei G; Deleris G; Bikfalvi A
    Clin Cancer Res; 2004 Jul; 10(13):4527-37. PubMed ID: 15240545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.
    Chlenski A; Liu S; Baker LJ; Yang Q; Tian Y; Salwen HR; Cohn SL
    Cancer Res; 2004 Oct; 64(20):7420-5. PubMed ID: 15492265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.
    Presta M; Dell'Era P; Mitola S; Moroni E; Ronca R; Rusnati M
    Cytokine Growth Factor Rev; 2005 Apr; 16(2):159-78. PubMed ID: 15863032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvessel density and expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived endothelial growth factor in oral squamous cell carcinomas.
    Li C; Shintani S; Terakado N; Klosek SK; Ishikawa T; Nakashiro K; Hamakawa H
    Int J Oral Maxillofac Surg; 2005 Jul; 34(5):559-65. PubMed ID: 16053878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion.
    Sutton A; Friand V; Brulé-Donneger S; Chaigneau T; Ziol M; Sainte-Catherine O; Poiré A; Saffar L; Kraemer M; Vassy J; Nahon P; Salzmann JL; Gattegno L; Charnaux N
    Mol Cancer Res; 2007 Jan; 5(1):21-33. PubMed ID: 17259344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.